Category: Practice

GODDYN advises TiGenix on agreement with Lonza

GODDYN has advised TiGenix (Euronext Brussels: TIG) on an agreement with Lonza for the manufacture of stem cell-based treatment of complex perianal fistulas in Crohn’s disease. TiGenix is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from allogeneic expanded adipose-derived stem cells (eASCs) in inflammatory and autoimmune diseases. Lonza is a global leader in biological and cell therapy manufacturing. TiGenix and Lonza announced today an agreement for…

Read More

GODDYN strengthens its legal work for TiGenix

GODDYN further strengthens its legal work for TiGenix (external link). TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with a commercial product and a strong clinical stage pipeline of adult stem cell programmes. Bart GODDYN (through GODDYN BVBA) will continue to cover a broad range of legal matters relevant to the bio-tech industry with a special focus on transactional and advisory work for TiGenix’s R&D, clinical,…

Read More

Seminar on R&D contracts

On 16 October 2014, Bart GODDYN spoke about industry perspectives of research & development contracts at the seminar of the European Academy for Taxes, Economics & Law in Berlin, Germany. Bart was invited for the eighth time as a speaker for this biannual conference. Topics included trade secrets, confidentiality, material transfer, intellectual property ownership and licensing.